Insilico Medicine and Eli Lilly published a framework in ACS Central Science outlining a vision for fully autonomous 'prompt‑to‑drug' pharmaceutical R&D that stitches generative AI models into every stage from target selection to candidate design. The perspective synthesizes recent advances in generative chemistry, protein modeling and automated synthesis planning, and argues for integrated pipelines that could compress discovery timelines. The paper is a research‑forward roadmap; while the authors highlight capabilities, they also acknowledge validation gaps and regulatory, reproducibility, and safety challenges ahead.